The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, randomized, controlled trial of nivolumab in combination with BMS-986253 or cabiralizumab in advanced hepatocellular carcinoma (HCC) patients.
 
Theodore Welling
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
 
Nina Beri
No Relationships to Disclose
 
Despina Siolas
Consulting or Advisory Role - Mabimmune; Mabimmune; Mabimmune; Mabimmune
Patents, Royalties, Other Intellectual Property - Cold Spring Harbor; Cold Spring Harbor; Cold Spring Harbor; Cold Spring Harbor
Other Relationship - Medal Pharmaceuticals; Medal Pharmaceuticals; Medal Pharmaceuticals; Medal Pharmaceuticals
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst)
 
Daniel Jacob Becker
No Relationships to Disclose
 
Hua Zhong
No Relationships to Disclose
 
Jennifer J. Wu
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
 
Paul Eliezer Oberstein
Consulting or Advisory Role - BTG; BTG; BTG; BTG; Celgene; Celgene; Celgene; Celgene; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Purdue Pharma; Purdue Pharma; Purdue Pharma; Purdue Pharma; TYME; TYME; TYME; TYME
Research Funding - Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Aduro Biotech (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck
 
Thomas Benjamin Karasic
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; Lilly; Lilly; Lilly; Lilly; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical; Syndax; Syndax; Syndax; Syndax; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical